Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Operating Activities
Net loss	$ (2,053,854)	$ (1,328,804)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	78,891	52,935
Amortization of debt discount	70,372	121,565
Fair value of stock options and warrants issued to consultants, employees and directors	171,591	152,067
Change in fair value of derivative instruments	(34,283)	(116,528)
Loss on disposal of Cryogenic shippers		2,613
Interest accrued on restricted cash	(148)	(226)
Changes in operating assets and liabilities:
Accounts receivable	(20,151)	48,220
Inventories	(739)
Other current assets	64,448	1,915
Accounts payable and accrued expenses	35,998	(205,513)
Accrued compensation and related expenses	128,667	9,293
Accrued interest	12,581	15,011
Net cash used in operating activities	(1,546,627)	(1,247,452)
Investing Activities
Purchases of intangible assets	(25,337)	(44,381)
Purchases of property and equipment	(44,477)	(210,851)
Net cash used in investing activities	(69,814)	(255,232)
Financing Activities
Repayments of convertible debentures payable	(576,628)
Payment of deferred financing costs	(130,770)
Proceeds from exercise of warrants	132,000
Repayments of related party notes payable	(30,000)	(30,000)
Net cash used in financing activities	(605,398)	(30,000)
Net change in cash and cash equivalents	(2,221,839)	(1,532,684)
Cash and cash equivalents, beginning of period	9,278,443	3,629,886
Cash and cash equivalents, end of period	7,056,604	2,097,202
Cash paid during the year for:
Interest	50,345	2,133
Income taxes	1,600	1,600
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Deferred financing costs in connection with equity financing		10,000
Fair value of shares issued for services		23,999
Offering costs in connection with equity financing included in accounts payable	27,500
Cashless exercise of warrants	$ 36